At the 6th China Pharmaceutical R&D and Innovation Summit, Yaozhi.com released the “2021 China Pharmaceutical R&D Comprehensive Strength Ranking”. The list comprehensively ranks the drug acceptance and approval status of each company in 2020, the R&D investment funds of pharmaceutical companies, the completion of clinical trials and the patent layout, and finally selects 100 companies including Jiangsu Hengrui Pharmaceutical and Zhengda Tianqing Pharmaceutical Group.

2021 China’s Drug R&D Comprehensive Strength Ranking
[table id=30 /] Interpretation of the domestic pharmaceutical research and development rankings in 2021
According to the 2021 R&D ranking of Chinese pharmaceutical companies, the top 100 companies on the list have a total of 559 new drug acceptance numbers in 2020, accounting for 48.44% of the 1,154 new drug acceptance numbers in the country, and 416 category 1 new drugs accounting for 46.83% of the country. This directly explains The enthusiasm of the top 100 companies in the research and development of new drugs.
According to corporate financial reports and corporate public information, the top 100 pharmaceutical companies on the R&D investment ranking list have invested a total of 65 billion yuan in research and development. Among them, 16 companies have invested more than 1 billion yuan in research and development. BeiGene invested the most, reaching 8.327 billion yuan, and the research and development expenditures of the top 100 companies are increasing year by year.
Compared with previous years’ list, a total of 66 companies have risen in 2021, of which 26 are newcomers, and major pharmaceutical companies have fierce competition in drug research and development.